GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study Investigating Efficacy of an Occluding Dentifrice for Dentine Hypersensitivity
Not Applicable
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Other: 0.454% w/w stannous fluoride (1100ppm fluoride)Other: 0.76% sodium monofluorophosphate (1000ppm fluoride)
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 409
- Registration Number
- NCT02705716
- Locations
- 🇬🇧
GSK Investigational Site, Wirral, United Kingdom
Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers
Phase 1
Completed
- Conditions
- Embryo Transfer
- Interventions
- Drug: Epelsiban (GSK557296)Drug: Placebo to match GSK557296
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 31
- Registration Number
- NCT02703181
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
Phase 3
Completed
- Conditions
- Malaria VaccinesMalaria
- Interventions
- Dietary Supplement: Vitamin ABiological: Candidate Plasmodium falciparum malaria vaccineBiological: MR-VacBiological: Stamaril
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 699
- Registration Number
- NCT02699099
- Locations
- 🇬🇭
GSK Investigational Site, Kumasi, Ghana
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers
Phase 1
Completed
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT02698553
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT02691325
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.
Phase 3
Completed
- Conditions
- Herpes Zoster
- Interventions
- Biological: Herpes Zoster Vaccine GSK1437173A
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8687
- Registration Number
- NCT02690207
- Locations
- 🇬🇧
GSK Investigational Site, Newtonabbey, United Kingdom
Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.
Phase 2
Completed
- Conditions
- Streptococcus AgalactiaeBacterial Infection Due to Streptococcus, Group B
- Interventions
- Biological: GBS Trivalent Vaccine
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT02690181
- Locations
- 🇧🇪
GSK Investigational Site, Ghent, Belgium
A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution
Phase 1
Completed
- Conditions
- Infections, Respiratory Tract
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 46
- Registration Number
- NCT02688361
- Locations
- 🇩🇪
GSK Investigational Site, Erfurt, Thueringen, Germany
A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers
Phase 1
Completed
- Conditions
- Tobacco Use Disorder
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT02688374
- Locations
- 🇨🇳
GSK Investigational Site, Beijing, China
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Phase 2
Completed
- Conditions
- Anaemia
- Interventions
- Drug: GSK1278863Drug: GSK1278863 matching Placebo
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 103
- Registration Number
- NCT02689206
- Locations
- 🇪🇸
GSK Investigational Site, Valladolid, Spain
© Copyright 2025. All Rights Reserved by MedPath